Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Conference Call February 7, 2023 4:30 PM ET

Company Participants

Jennifer Viera – Investor Relations

Jay Luly – President and Chief Executive Officer

Paul Mellett – Chief Financial Officer

Tara Kieffer – Senior Vice President-New Product Strategy Development

Conference Call Participants

Joe Kim – RBC

Luke Herrmann – Baird

Roanna Ruiz – SVB Securities

Matthew Hershenhorn – Oppenheimer

Ed Arce – H.C. Wainwright & Co

Eric Joseph – JPMorgan

Roy Buchanan – JMP Securities

Operator

Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal First Quarter Ended December 31, 2022 Financial Results Conference Call. At this time all participants are in a listen only mode. [Operator Instructions] Please be advised that today’s conference is being recorded.

I’d now like to hand the conference over to Jennifer Viera, Investor Relations. Please go ahead.

Jennifer Viera

Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal first quarter 2023 financial results was issued this afternoon and is available on our website. On the call today are Dr. Jay Luly, President and Chief Executive Officer; Paul Mellett, our Chief Financial Officer; and other members of Enanta’s senior management team.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent Form 10-K and other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call.

I’d now like to turn the call over to Dr. Jay Luly, President and CEO. Jay?

Jay Luly

Thank you, Jennifer, and good afternoon, everyone. At Enanta, our mission continues to be to leverage our expertise in small molecule drugs to discover and develop groundbreaking medicines. Our fiscal first quarter of 2023 set up a strong data-rich year, positioning us to potentially drive value for our company as we advance our expanding pipeline.

Today, I will start by detailing recent advances in our COVID-19 program and then comment

on our broad respiratory syncytial virus, or RSV, program as well as touch base on the rest of our pipeline. Beginning with our COVID-19 program, our lead asset is EDP-235, the clinical stage, once-daily, orally dosed inhibitor of the coronavirus 3CL protease, which is currently being evaluated in an ongoing Phase 2 study known as SPRINT. We are pleased to announce that the study has completed enrollment beyond the initial target.